Enanta Pharmaceuticals Inc (ENTA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.41 (-0.88%), Market cap $0.39B, 52-week low–high $5.75 ~ $16.85.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treat
Financial statements, price targets, institutional (13F) holdings and related news for Enanta Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Enanta Pharmaceuticals Inc trades at $12.41 (-0.88%). Real-time quotes and charts are available on BlackAll Trade.
Enanta Pharmaceuticals Inc has a market cap of about $0.39B.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is i